📊 PMVP Key Takeaways
Is PMV Pharmaceuticals, Inc. (PMVP) a Good Investment?
PMV Pharmaceuticals is a clinical-stage biopharmaceutical company with deteriorating fundamentals: revenue collapsed 40.5% YoY to just $980K while operating losses remained at $19M, creating an unsustainable burn rate with only ~2 years of cash runway. While the balance sheet is solid with $39.1M cash and zero debt, the absence of meaningful revenue and inability to approach breakeven despite substantial R&D spending presents severe near-term execution risk.
PMV Pharmaceuticals, Inc. Key Strengths (PMVP)
- Strong balance sheet with $39.1M cash reserves and zero debt
- Excellent liquidity position with 11.14x current ratio
- Sufficient capital runway to fund operations approximately 2 years
- Manageable liability burden ($8.6M total liabilities)
PMVP Stock Risks: PMV Pharmaceuticals, Inc. Investment Risks
- Severe revenue decline of 40.5% YoY to near-zero revenue levels
- Massive operating losses of $19M on only $980K revenue (unsustainable)
- Heavy cash burn rate of $19.7M annually with no offsetting revenue growth
- Typical high-execution risk associated with clinical-stage pharmaceutical development
- Limited financial runway despite adequate current cash reserves
Key Metrics to Watch
- Revenue trajectory and pipeline advancement milestones
- Quarterly cash burn rate and months of runway remaining
- Strategic partnerships, licensing deals, or clinical trial progression announcements
PMV Pharmaceuticals, Inc. (PMVP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.14x current ratio provides a solid financial cushion.
PMVP Profit Margin, ROE & Profitability Analysis
PMVP vs Healthcare Sector: How PMV Pharmaceuticals, Inc. Compares
How PMV Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PMV Pharmaceuticals, Inc. Stock Overvalued? PMVP Valuation Analysis 2026
Based on fundamental analysis, PMV Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PMV Pharmaceuticals, Inc. Balance Sheet: PMVP Debt, Cash & Liquidity
PMVP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PMV Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.44 indicates the company is currently unprofitable.
PMVP Revenue Growth, EPS Growth & YoY Performance
PMV Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
PMVP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PMV Pharmaceuticals, Inc. (CIK: 0001699382)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080643.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080603.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080616.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080614.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_080642.xml | View → |
❓ Frequently Asked Questions about PMVP
What is the AI rating for PMVP?
PMV Pharmaceuticals, Inc. (PMVP) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PMVP's key strengths?
Claude: Strong balance sheet with $39.1M cash reserves and zero debt. Excellent liquidity position with 11.14x current ratio.
What are the risks of investing in PMVP?
Claude: Severe revenue decline of 40.5% YoY to near-zero revenue levels. Massive operating losses of $19M on only $980K revenue (unsustainable).
What is PMVP's revenue and growth?
PMV Pharmaceuticals, Inc. reported revenue of $980.0K.
Does PMVP pay dividends?
PMV Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find PMVP SEC filings?
Official SEC filings for PMV Pharmaceuticals, Inc. (CIK: 0001699382) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PMVP's EPS?
PMV Pharmaceuticals, Inc. has a diluted EPS of $-0.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PMVP's fundamental grade?
Based on our AI fundamental analysis in June 2026, PMV Pharmaceuticals, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PMVP stock overvalued or undervalued?
Valuation metrics for PMVP: ROE of -20.5% (sector avg: 15%), net margin of -1,840.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PMVP's AI grade for 2026?
Our dual AI analysis gives PMV Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PMVP's free cash flow?
PMV Pharmaceuticals, Inc.'s operating cash flow is $-19.7M, with capital expenditures of $0.0. FCF margin is -2,008.1%.
How does PMVP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,840.6% (avg: 12%), ROE -20.5% (avg: 15%), current ratio 11.14 (avg: 2).